Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Feb;27(Suppl 1):17-23.
doi: 10.3747/co.27.5407. Epub 2020 Feb 1.

Immunotherapy in soft-tissue sarcoma

O Ayodele  1 , A R Abdul Razak  1
Affiliations
Review

Immunotherapy in soft-tissue sarcoma

O Ayodele et al. Curr Oncol. 2020 Feb.

Abstract

Soft-tissue sarcoma (sts) is a rare mesenchymal malignancy that accounts for less than 1% of all adult tumours. Despite the successful advancement of localized therapies such as surgery and radiotherapy, these tumours can, for many, recur-often with metastatic disease. In the advanced setting, the role of systemic therapies is modest and is associated with poor survival. With the discovery of immunotherapies in other tumour types such as melanoma and lung cancer, interest has been renewed in exploring immunotherapy in sts. The biology of some stss makes them ripe for immunotherapy intervention; for example, some stss might have chromosomal translocations resulting in pathognomonic fusion products that have been shown to express cancer/testis antigens. Here, we present a targeted review of the published data and ongoing clinical trials for immunotherapies in patients with sarcoma, which comprise immune checkpoint inhibitors, adoptive cell therapies, and cancer vaccines.

Keywords: Adoptive cell therapy; alveolar soft-part sarcoma; cancer vaccines; checkpoint inhibitors; immunotherapy; soft-tissue sarcoma; undifferentiated pleomorphic sarcoma.

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST DISCLOSURES We have read and understood Current Oncology’s policy on disclosing conflicts of interest, and we declare the following interests: ARAR has a consulting role for Lilly, Merck, and Boehringer Ingelheim, and has received research funding from casi Pharmaceuticals, Boehringer Ingelheim, Lilly, Novartis, Deciphera Pharmaceuticals, Karyopharm Therapeutics, Pfizer, Roche/Genentech, Boston Biomedical, Bristol–Myers Squibb, MedImmune, Amgen, GlaxoSmithKline, Blueprint Medicines, Merck, AbbVie, and Adaptimmune. OA has no conflicts of interested to declare.

References

    1. Karavasilis V, Seddon BM, Ashley S, Al-Muderis O, Fisher C, Judson I. Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identification of prognostic factors in 488 patients. Cancer. 2008;112:1585–91. doi: 10.1002/cncr.23332. - DOI - PubMed
    1. Ducimetiere F, Lurkin A, Ranchere-Vince D, et al. Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing. PLoS One. 2011;6:e20294. doi: 10.1371/journal.pone.0020294. - DOI - PMC - PubMed
    1. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-KIT in human gastrointestinal stromal tumours. Science. 1998;279:577–80. doi: 10.1126/science.279.5350.577. - DOI - PubMed
    1. Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumours. Science. 2003;299:708–10. doi: 10.1126/science.1079666. - DOI - PubMed
    1. Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet. 2004;364:1127–34. doi: 10.1016/S0140-6736(04)17098-0. - DOI - PubMed